Amarin to Present at the Cowen and Company Healthcare Conference
DUBLIN and MYSTIC, Conn., March 3 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that John F. Thero, Chief Financial Officer, is scheduled to present at Cowen and Company's 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at 8:45 am Eastern Time. This conference will be held at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available at the following URL:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AMRN&item_id=2757838
A replay of the presentation will be available at the same URL for 30 days.
About Amarin
Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrollment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: |
|
Investor Contact Information: |
|
John F. Thero |
|
Chief Financial Officer |
|
In US: +1 (860) 572 4979 |
|
Gitanjali Ogawa |
|
The Trout Group |
|
In US +1 (646) 378-2949 |
|
International Media Contact Information: |
|
Mark Swallow or David Dible |
|
Citigate Dewe Rogerson |
|
In UK: +44 (0)207 638 9571 |
|
SOURCE Amarin Corporation plc
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article